Quick Facts

• Relief of Abdominal Discomfort: Used for the symptomatic management of pain and cramps.
• Irritable Bowel Syndrome (IBS) Management: Indicated for functional bowel disorders, including IBS.
• Symptomatic Treatment: Helps manage symptoms such as bowel disturbance, flatulence, and bloating related to gut spasm.

---

Therapeutic Focus: Symptomatic Relief of Bowel Spasm

Duspatalin 135 is indicated for the symptomatic treatment of conditions involving gastrointestinal smooth muscle spasm. Its primary use is in the management of symptoms associated with Irritable Bowel Syndrome (IBS), which is characterized by abdominal pain, cramping, and disturbances in bowel function.

This medication works to reduce the intensity of intestinal muscle spasms without negatively affecting the normal movement of the digestive tract. By acting directly on the smooth muscle of the gut, it provides relief from the painful contractions and discomfort that are a hallmark of IBS and related functional bowel disorders, such as chronic irritable colon, spastic constipation, and mucous colitis.

The benefits of using this agent are centered on the amelioration of predominant symptoms, which include the reduction of abdominal pain and cramps. Furthermore, it helps alleviate associated issues like bloating and flatulence. The therapeutic goal is to improve overall symptomatic control and assist in the management of recurrent digestive tract discomfort.

Eligibility Map: Who can and cannot use Duspatalin 135 — Official Regulatory Information

This section details the officially documented eligibility and non-eligibility rules for Duspatalin 135 (Mebeverine Hydrochloride 135 mg tablets), strictly based on government regulatory documentation (e.g., Summary of Product Characteristics, Prescribing Information).

---

Eligibility Scope

Classification	Eligibility Status as Stated in Label
Populations for whom use is allowed	Adults (including the elderly).
Populations for whom use is not recommended	Children and adolescents below 18 years (due to insufficient data on safety and efficacy). Pregnant women (due to no or limited human data).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance or excipients. Patients with rare hereditary problems like galactose intolerance or Lapp lactase deficiency.
Pregnancy and lactation eligibility status	Pregnancy: Not recommended. Lactation: Should not be used.

---

Condition-Specific Eligibility Rules

• Organ Function: No dosage adjustment is deemed necessary for elderly, renal impaired, and hepatic impaired patients. However, use should be with caution in cases of advanced liver or kidney disease.

---

Resulting Eligibility Structure

Regulatory documents define who can and cannot use the medicine through absolute contraindications that prohibit use entirely (e.g., allergies and metabolic disorders related to excipients). Use is strongly not recommended for the pediatric population and for women who are pregnant or breastfeeding due to insufficient or limited clinical data. Adults are the approved population, and while use is permitted in the elderly and those with mild organ impairment, a lack of dedicated posology studies is noted in the official profile.

Interactions with other medicines and products

Official regulatory documentation, including the Summary of Product Characteristics (SmPC), defines the interaction profile of Duspatalin 135 (Mebeverine Hydrochloride) primarily by the absence of documented drug-drug interaction studies.

Interaction Scope

The regulatory position is that formal interaction studies with other medicinal products have generally not been performed.

Property	Documentation Status
Medicinal product categories with documented interactions	None listed
Specific interacting medicines	None listed
Mechanistic basis of interactions	None documented

Consequently, the official labeling does not list any substances that are known to alter Mebeverine's drug levels through metabolic pathways (such as CYP enzymes) or transporter mechanisms. There are also no formally listed contraindicated combinations with other medicines and no mandatory timing rules requiring separation of doses documented in the regulatory text.

Documented Substance Interaction

Alcohol (Ethanol) is the only substance specifically investigated for interaction according to regulatory sources. Official studies have demonstrated the absence of any interaction between Mebeverine Hydrochloride and ethanol.

Targeting Ion Channels for Direct Muscle Relaxation

The drug's primary action is to act as a modulator of ion channel permeability within the smooth muscle cells of the intestinal wall. It achieves this by directly blocking Voltage-Dependent Calcium Channels ( VDCCs), which restricts the influx of Ca^2+ essential for muscle contraction. This interference with the Ca^2+ signaling cascade reduces the capacity of muscle fibers for prolonged contraction.

Multi-Layered Intracellular and Local Modulation

Mebeverine employs a polyvalent mechanism, utilizing secondary targets. It inhibits certain Phosphodiesterase (PDE) enzymes, promoting cellular relaxation by increasing key messenger molecules. Furthermore, the drug modulates Sodium Channels ( Na^+), which helps stabilize the muscle cell membrane and reduce local tissue excitability. This combination of effects results in the modulation of intestinal muscle tone and motility, while exhibiting low systemic anticholinergic activity.

Selectivity for Hypertonicity Over Systemic Pathways

The mechanism is highly localized and selective, focusing on the muscle itself rather than broad nerve pathways. This direct action is characterized by minimal influence on systemic autonomic nervous system receptors. This specificity ensures the physiological consequence is the localized reduction of hypertonicity.

How to Use Duspatalin 135

The Mebeverine Hydrochloride 135 mg film-coated tablet is intended for oral administration.

---

Dosing and Scheduling

Instruction Entity	Administration Rule
Standard Adult Dose	One 135 mg tablet per dose.
Frequency Pattern	Three times a day (TID).
Timing in Relation to Meals	To be taken before meals (pre-prandially).

---

Procedural Instructions

Proper use of the 135 mg tablet requires specific intake conditions to ensure the intended delivery of the active substance. The tablet must be swallowed whole with an adequate quantity of water; it should not be crushed or chewed.

If a scheduled dose is missed, the missed dose should be omitted entirely, and the next dose should be taken at the regular, established time. A double dose should not be taken to compensate for a missed dose.

Use in Specific Populations

No dose adjustment for the standard 135 mg regimen is typically required for older adults, nor is adjustment mandated for patients with known renal impairment or hepatic impairment.

Duspatalin 135: Recent Clinical Evidence

This section describes the types of research and clinical studies that have explored the use of Duspatalin (mebeverine) in the context of symptoms associated with Irritable Bowel Syndrome (IBS) and what findings describe patterns observed in the studies. This information is intended to help contextualize how the evidence landscape has evolved and does not provide personal medical advice.

Evidence for Use in Irritable Bowel Syndrome (IBS)

Researchers conducted studies, including randomized controlled trials (RCTs), to examine mebeverine's role in the setting of IBS symptoms. These studies primarily focused on adult patients whose condition is characterized by fluctuating or episodic manifestations. Research examined outcomes related to physical discomfort, specifically measuring the intensity and frequency of abdominal pain or spasms, which are key outcomes capturing phases of heightened symptom activity in IBS. These controlled studies reported how symptoms evolved in the observed populations over defined time intervals. The findings describe patterns observed in the studies regarding patient-reported experiences of symptom patterns. This evidence contributes to understanding observed symptom patterns.

Comparative Studies Against Placebo and Other Treatments

Research has explored how Duspatalin was evaluated in trials where it was compared against a placebo (an inactive substance) or against other existing treatments was observed in the studies. These comparative studies assessed patient-reported outcomes describing perceived discomfort and monitoring how this and other outcomes reflecting daily functioning were measured in the groups studied. Data show patterns related to symptom measurement changes recorded in these comparative settings. Direct comparative evidence against newer therapeutic options is limited, and findings were heterogeneous when research examined different comparator agents. Research provides context but not individual predictions regarding whether an individual will experience similar patterns.

Long-Term Studies and Follow-up Duration

The majority of the research involves short-term follow-up durations. This means that the long-term outcomes are not fully established. Some open-label or observational studies have examined outcomes for intermediate periods, such as several months, but the data are still emerging regarding the durability of any observed patterns. Therefore, long-term outcomes are not fully established, and information on extended observation periods in conditions presenting with cycles of stability and flare-ups remains insufficient.

Evidence in Special Populations

Research was studied for the use of Duspatalin primarily in the general adult IBS population. Data for certain groups remain insufficient. For instance, while some studies were observed in older adults and adolescents with IBS, the sample sizes were modest, and specific findings for these subgroups are uncertain. There is limited information for individuals with specific comorbidities. Evidence describing the use of Duspatalin in populations like pregnant individuals is limited, meaning that the results apply only to the populations studied in the existing trials.

What is Still Uncertain About Duspatalin 135

The overall evidence quality varies across studies, with many controlled trials being older or having modest sample sizes. This contributes to overall uncertainty. Research highlights what is known, but also clarifies that comparative evidence is lacking against many of the newest available pharmacological treatments for IBS. Researchers note that evidence is limited by the heterogeneity in patient populations and the different scales used to measure symptom intensity or variability across trials. Therefore, findings describe group patterns, not personal outcomes, and ongoing research is ongoing to explore these evidence gaps.

Common questions about Duspatalin 135 (FAQ)

Q: What are the typical indications listed in official documents for Duspatalin 135?

The official indications listed in regulatory documents are for the symptomatic treatment of abdominal pain and cramps, bowel disturbance, and intestinal discomfort related to Irritable Bowel Syndrome (IBS).

---

Q: Does Duspatalin 135 come in different formulations (e.g., liquid, capsule)?

The medicine is available as the 135 mg film-coated tablet (which is a standard-release form) and is also available as a 200 mg prolonged-release hard capsule (often referred to as the Retard formulation). The official product information notes that the use conditions and frequency of administration differ between these two forms.

---

Q: Is Duspatalin 135 meant for long-term or short-term use?

Official regulatory guidance on the maximum duration of continuous use is not typically defined. The product information describes the medicine as suitable for use until satisfactory symptom relief is achieved. Once symptoms are resolved, treatment may be gradually discontinued.

---

Q: Are there any common side effects people report when taking Duspatalin 135?

Official safety documents state that the most prominently categorized adverse events are hypersensitivity reactions, such as skin rashes. For many other reported effects, including those affecting the stomach or intestines, the frequency is often classified as 'Not Known' based on available post-marketing data.

---

Q: Is it common to feel dizzy after taking Duspatalin 135?

Based on the official safety profile, dizziness is generally not listed as a reported side effect of the medicine.

---

Q: Is Duspatalin 135 safe for elderly patients?

Regulatory documents confirm that no dose adjustment is typically needed for older adults in the standard regimen. However, official documents state that caution is warranted in patients who have advanced liver or kidney disease.

---

Q: Does Duspatalin 135 affect blood pressure?

According to official regulatory documentation, adverse reactions specifically related to the cardiovascular system, such as changes in blood pressure, are not listed in the safety profile of the medicine.

---

Q: What distinguishes Duspatalin 135 from other smooth muscle relaxants?

This medicine is classified as a musculotropic antispasmodic, meaning it acts directly on the muscle tissue of the gut. Its mechanism is noted for exhibiting a minimal influence on the autonomic nervous system, focusing on the smooth muscle with low systemic effects.

---

Q: How is the absorption of Duspatalin 135 described in medical literature?

Official pharmacokinetic information indicates that the active ingredient is rapidly and completely absorbed by the body following oral intake.

---

Q: Can Duspatalin 135 cause constipation or diarrhea?

Regulatory texts mention diarrhea as a reported gastrointestinal disorder in post-marketing data. Conversely, constipation is generally not listed as a specific adverse event associated with this medication.

---

Q: Does Duspatalin 135 impact the ability to drive or use machinery?

Official regulatory documents state that the medicine is unlikely to affect a person's ability to drive a vehicle or operate heavy machinery.

---

Q: What is the primary way Duspatalin 135 is eliminated from the body?

After being completely metabolized, the active ingredient is eliminated almost entirely as various metabolites via the urine, with only a small amount passing through the feces.

---

Q: Does Duspatalin 135 affect liver function tests?

Official product information does not list abnormalities in liver function tests or specific hepatic adverse events in the Undesirable Effects section.

---

Q: What happens in the body when Duspatalin 135 is metabolized?

The active ingredient is completely metabolized in the body, primarily through a process known as hydrolysis. The main resulting substance, mebeverine alcohol, is eliminated and is understood to have no antispasmodic effect.

---

Q: Are there patient support programs or information leaflets for Duspatalin 135?

The Patient Information Leaflet (PIL) is a regulatory document that is required to be included in the medicine's packaging. Details about external patient support programs are not typically found in the official drug label itself.

How to Store and Dispose of Duspatalin 135

Storage and disposal of Duspatalin 135 (mebeverine hydrochloride) must follow specific requirements defined in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

• Temperature and Handling: The tablets must be stored at a temperature not greater than 30 C; it is explicitly stated to not freeze the medicine.
• Protection: The product must be protected from light and kept in a dry place in its original package.
• Child Safety: It is a mandatory requirement to keep this medicine out of the sight and reach of children.
• Stability: Do not use the tablets after the expiry date printed on the carton.

Disposal Instructions

Medicines must not be disposed of via wastewater or standard household trash. Unused or expired product should be returned to a pharmacist for disposal in accordance with local regulatory requirements for pharmaceutical waste.